Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme

por Dungan, K. M., Raz, I., Skrivanek, Z., Sealls, W., Fahrbach, J. L.
Publicado 2016

Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study

por Morieri, M. L., Raz, I., Consoli, A., Rigato, M., Lapolla, A., Broglio, F., Bonora, E., Avogaro, A., Fadini, G. P.
Publicado 2023

Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement

por Unnikrishnan, A G, Tibaldi, J, Hadley-Brown, M, Krentz, A J, Ligthelm, R, Damci, T, Gumprecht, J, Gerő, L, Mu, Y, Raz, I
Publicado 2009

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

por Masmiquel, L., Leiter, L. A., Vidal, J., Bain, S., Petrie, J., Franek, E., Raz, I., Comlekci, A., Jacob, S., van Gaal, L., Baeres, F. M. M., Marso, S. P., Eriksson, M.
Publicado 2016